Five Prime Goes Public in Upsized Offering, Aerie Joins IPO Parade
This year’s flurry of initial public offering (IPO) activity continued Wednesday, as protein and antibody drug developer Five Prime Therapeutics Inc. priced an upsized offering to gross $64.5 million and ophthalmology firm Aerie Pharmaceuticals Inc. added its name to biotech’s IPO queue.
And more news is expected.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter